Subsequent to a meeting with the EMA, Can-Fite BioPharma Ltd. (NYSEMKT:CANF) says it now has sufficient regulatory guidance to conduct a pivotal Phase 3 clinical trial evaluating Namodenoson in hepatocellular carcinoma patients with Child Pugh Class B7 (moderately severe) cirrhosis.
The primary endpoint of the 450-subject study will be overall survival (OS).
Namodenoson failed to beat placebo in OS in a Phase 2 trial.
https://seekingalpha.com/news/3580387-can-fite-advancing-namodenoson-in-liver-cancer
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.